Atlas Trials

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Clinical trial NCT04772287 · NOT_YET_RECRUITING

Trial details

NCT number
NCT04772287
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2021-03-31
Primary completion
2026-12-30
Enrollment
341

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.